Chargement en cours...
Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis
In this issue of Cancer Cell, Lionakis et al. demonstrate that the combination of temozolomide, etoposide, doxorubicin, dexamethasone, rituximab, and the Bruton tyrosine kinase (BTK) inhibitor ibrutinib induced frequent responses in patients with primary central nervous system lymphoma but was assoc...
Enregistré dans:
| Publié dans: | Cancer Cell |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5572136/ https://ncbi.nlm.nih.gov/pubmed/28552326 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2017.05.004 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|